Table 1:
Patient Characteristics
| Variable | Overall (n=10603) |
Mod-Severe AI (n=1399) |
No - Mild AI (n=9204) |
p-value |
|---|---|---|---|---|
| Age > 60, (years) | 4725 (44.6%) | 845 (60.4%) | 3880 (42.2%) | <0.001 |
| Female Gender | 2357 (22.2%) | 375 (26.8%) | 1982(21.5%) | <0.001 |
| African American | 2742 (25.9%) | 316(22.6%) | 2426 (26.4%) | 0.003 |
| BSA<2 | 4617(43.5%) | 739(52.8%) | 3878(42.1%) | <0.001 |
| Blood Type O | 5071 (48.4%) | 678 (49.1%) | 4393 (48.3%) | 0.587 |
| Ischemic Diagnosis | 4738 (45.0%) | 665 (47.8%) | 4073 (44.6%) | 0.026 |
| Mild Pre-Implant AI | 3241 (30.6%) | 613 (43.8%) | 2628 (28.6%) | <0.001 |
| Comorbid Conditions | ||||
| Diabetes | 389 (3.8%) | 45 (3.3%) | 344 (3.8%) | 0.381 |
| Pulmonary HTN | 1022(10.0%) | 153 (11.5%) | 869 (9.7%) | 0.045 |
| PVD | 229(2.2%)' | 43 (3.2%) | 186(2.1%) | 0.009 |
| Prior CVA | 90 (0.9%) | 12 (0.9%) | 78 (0.9%) | 0.924 |
| Atrial Arrhythmia | 1548(20.8%) | 190(22.5%) | 1358(20.6%) | 0.196 |
| Active Smoker | 538 (7.1%)' | 62 (7.1%) | 476(7.1%)' | 0.016 |
| CKD | 1937(25.0%) | 258 (28.4%) | 1679(24.5%) | 0.012 |
| NYHA Class | 0.665 | |||
| Class I & II | 103 (1.0%) | 14(1.1%) | 89 (1.0%) | |
| Class III | 1840(18.55) | 232 (17.6%) | 1608(18.6%) | |
| Class IV | 8018(80.5%) | 1074(81.4%) | 6944 (80.4%) | |
| INTERMACS Profile | 0.005 | |||
| INTERMACS 1 | 1644(15.6%) | 188 (13.5%) | 1456(15.9%) | |
| INTERMACS 2 | 3806(36.1%) | 516(37.1%) | 3290 (36.0%) | |
| INTERMACS 3 | 3420 (32.4%) | 429 (30.9%) | 2991 (32.7%) | |
| INTERMACS 4–7 | 1672(15.9%) | 257(18.5%) | 1415(15.5%) | |
| IV Inotropes | 8713(82.5%) | 1153(82.7%) | 7560 (82.4%) | 0.806 |
| Events During Index Hospitalization | ||||
| ECMO | 321 (3.0%) | 28 (2.0%) | 293 (3.2%) | 0.016 |
| IABP | 2124(20.0%) | 238 (17.0%) | 1886(20.5%) | 0.002 |
| Cardiac Arrest | 472 (4.5%)' | 60 (4.3%) | 412 (4.5%)' | 0.751 |
| Dialysis | 247 (2.3%) | 31 (2.2%) | 216(2.4%) | 0.762 |
| Intubated | 1082(10.2%) | 135 (9.7%) | 947 (10.3%) | 0.462 |
| Device Configuration | 0.428 | |||
| CF-LVAD Alone | 10279 (96.9%) | 1361 (97.3%) | 8918(96.9%) | |
| BiVAD | 324(3.1%) ' | 38 (2.7%) | 286(3.1%)' | |
| CF-LVAD Type | <0.001 | |||
| Axial | 8857(83.5%) | 1256 (89.8%) | 7601 (82.6%) | |
| Centrifugal | 1746(16.5%) | 143 (10.2%) | 1603(17.4%) | |
| Time on Device (mos), median | 13.4(6.0–26.3) | 25.6(13.6–40.9) | 12.1 (5.5–23.6) | <0.001 |
| Device Strategy | <0.001 | |||
| Bridge to Recovery | 44 (0.4%) | 6 (0.4%) | 38 (0.4%) | |
| Bridge to Transplant | 6047 (57.0%) | 676(48.3%) | 5371 (58.4%) | |
| Destination Therapy | 4474 (42.2%) | 716(51.2%) | 3759 (40.8%) | |
| Other/Rescue | 37 (0.4%) | 1 (0.1%) | 36 (0.4%) | |
BSA, body surface area; AI, aortic insufficiency; HTN, hypertension; PVD, peripheral vascular disease; CVA, cerebrovascular accident; CKD, chronic kidney disease; ECMO, extracorporeal membranous oxygenation; IABP, intraaortic balloon pump; CF-LVAD, continuous flow left ventricular assist device; BiVAD, biventricular assist device.